Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
The diagnosis of Polycythemia Vera is a rigorous process of exclusion and confirmation. Because erythrocytosis can be caused by numerous benign conditions, such as chronic lung disease, sleep apnea, or even dehydration, distinguishing true neoplastic polycythemia from secondary causes is paramount. At Liv Hospital, we adhere to the 2016 World Health Organization (WHO) revised criteria, which integrate clinical, morphological, and genetic data. This multi faceted approach ensures that no case is missed and that patients are not subjected to unnecessary treatment for non malignant conditions.
The diagnostic journey typically begins with a Complete Blood Count (CBC).
The WHO criteria established lower thresholds for diagnosis to capture “masked” Polycythemia Vera.
While isolated erythrocytosis can occur, PV is more commonly associated with leukocytosis (elevated white cell count) and thrombocytosis (elevated platelet count). The presence of elevated counts in three lineages (panmyelosis) is a strong clinical indicator of a myeloproliferative neoplasm rather than a secondary cause.
The peripheral blood smear often shows normocytic, normochromic red blood cells. In patients with iron deficiency (often due to occult bleeding or prior phlebotomy), the cells may appear microcytic and hypochromic. The presence of giant platelets or immature white blood cells may suggest early progression to myelofibrosis.
The discovery of the JAK2 mutation revolutionized the diagnosis of MPNs.
Peripheral blood DNA is screened for the JAK2 V617F mutation using highly sensitive allele specific PCR techniques.
In patients with sustained erythrocytosis who test negative for V617F, testing for mutations in JAK2 Exon 12 is mandatory. These patients typically present with isolated erythrocytosis and may have lower white cell and platelet counts compared to V617F positive patients.
While genetic testing is powerful, the bone marrow biopsy remains a Major Criterion in the WHO classification to differentiate PV from other MPNs like Essential Thrombocythemia or early Primary Myelofibrosis.
The hallmark of PV is a hypercellular marrow for the patient’s age. This cellularity is driven by panmyelosis, an expansion of all three hematopoietic lineages.
Pathologists look for a specific appearance of the megakaryocytes (platelet forming cells). In PV, they are typically increased in number and display a “pleomorphic” appearance, meaning they vary in size from small to giant. They often form loose clusters. This contrasts with the “staghorn” megakaryocytes seen in Essential Thrombocythemia or the dense clusters and fibrosis seen in Primary Myelofibrosis.
A silver stain is applied to assess the level of fibrosis. At diagnosis, most PV patients have little to no fibrosis (MF 0 or MF 1). Significant fibrosis suggests the disease may have already progressed to the “spent phase” or was Primary Myelofibrosis from the start.
Measuring serum erythropoietin levels is a critical step in the differential diagnosis.
In Polycythemia Vera, the autonomous production of red cells suppresses the renal production of EPO. Therefore, serum EPO levels are typically low or undetectable.
In secondary erythrocytosis, the high red cell count is driven by high EPO levels. This occurs in response to hypoxia (lung disease, high altitude, smoking) or pathological EPO production (kidney tumors, liver tumors). A normal or high EPO level essentially rules out Polycythemia Vera in most clinical scenarios.
A definitive diagnosis requires meeting either all three Major Criteria or the first two Major Criteria plus the Minor Criterion.
Biochemistry: Subnormal serum erythropoietin level.
The diagnostic process must rigorously exclude other causes of high hematocrit.
This condition is characterized by a normal red cell mass but a decreased plasma volume. It is often seen in middle aged men with hypertension, obesity, and smoking history. The blood appears concentrated because of dehydration or vascular contraction, not because of excess cell production.
Chronic Obstructive Pulmonary Disease (COPD) and Sleep Apnea are common causes of secondary polycythemia. Pulse oximetry and sleep studies may be required to rule these out.
Rare genetic conditions cause hemoglobin to hold onto oxygen too tightly, causing tissue hypoxia and secondary polycythemia. This is suspected in young patients with a family history of polycythemia but no JAK2 mutation.
Send us all your questions or requests, and our expert team will assist you.
The biopsy provides critical information about the state of your bone marrow, including the amount of scarring (fibrosis). This establishes a baseline to monitor disease progression and helps distinguish PV from other similar blood cancers.
Dehydration can cause a temporarily high hematocrit, but it does not cause the JAK2 mutation or bone marrow changes. Rehydration will correct the blood counts in a healthy person, but not in a PV patient.
This refers to patients who have the biology of PV (JAK2 mutation, marrow changes) but whose hemoglobin levels fall below the traditional high threshold, often appearing in the “high normal” range. This can happen in early disease or if iron deficiency is limiting red cell production.
No. In fact, secondary causes like smoking, sleep apnea, and lung disease are much more common causes of high hematocrit than Polycythemia Vera.
Genetic testing for JAK2 is a standard of care diagnostic test for suspected blood cancers and is typically covered, but coverage policies vary by provider and region.
Your Comparison List (you must select at least 2 packages)
